MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,765.36
-0.47%
NASDAQ 100
$30,725.81
-1.39%
DOW JONES
$51,232.00
+0.10%
NASDAQ Composite
$27,193.34
-1.25%
RUSSELL 2000
$2,775.70
-0.05%
CBOE VIX
$15.41
+2.19%
Sector Heatmap
Technology-1.79%
Financials+0.89%
Healthcare-0.39%
Consumer Cycl+0.31%
Consumer Staples+2.11%
Energy+2.97%
Industrials+0.33%
Materials+0.59%
Real Estate+0.69%
Utilities-0.19%
Comm Services+0.73%
SPRO — Spero Therapeutics, Inc. Common Stock
NasdaqSpero Therapeutics, Inc. Common Stock
$1.14
-0.03(-2.56%)
- O
- 1.20
- H
- 1.22
- L
- 1.13
- V
- 718.84K
⏱️ End-of-day dataAs of Oct 8, 2026
SPRO — Latest News & Headlines
6 StoriesNew Spero hires get stock awards, but vesting starts after a year - Stock Titan
New Spero hires get stock awards, but vesting starts after a year Stock Titan
Spero Therapeutics grants 556,000 awards and gets USD 6.00 target for Spero Therapeutics stock - AD HOC NEWS
Spero Therapeutics grants 556,000 awards and gets USD 6.00 target for Spero Therapeutics stock AD HOC NEWS
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) The Manila Times
SPRO Q2 2026 Earnings: Narrower-Than-Expected Loss, Yet Shares Slip - Quarterly Earnings Report - https://www.dars.gov.et/
SPRO Q2 2026 Earnings: Narrower-Than-Expected Loss, Yet Shares Slip - Quarterly Earnings Report https://www.dars.gov.et/
Spero Therapeutics targets SP001 trial for 2027: Spero Therapeutics stock gains 3.85 percent - AD HOC NEWS
Spero Therapeutics targets SP001 trial for 2027: Spero Therapeutics stock gains 3.85 percent AD HOC NEWS
Russian plague outbreak could boost these under-the-radar pharma stocks - Invezz
Russian plague outbreak could boost these under-the-radar pharma stocks Invezz